How would you sequence lifileucel (TIL therapy) in a patient with metastatic melanoma who is BRAF wild-type (BRAF WT) and progressed on adjuvant Nivolumab?

The FDA-approved label for Amtagvi is for BRAF wild-type metastatic melanoma patients who progressed following anti-PD-1 containing immune checkpoint therapy. Thus, progression following ipi/nivo would certainly meet the indication for TIL therapy. What you will have to assess though is whether the ...

I am presuming that this patient progressed "while receiving" nivolumab and is not someone who progressed a year later? The approach may change a bit if the patient is in the second scenario because opdualag may come into play in such a patient.

However, presuming that this patient is truly anti-PD1 ...